Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
Chetan Nagaraja
Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
Samuel Daniels
Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
Zoe A Fisk
Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada; University of Ottawa Brain and Mind Research Institute, Ottawa, Canada; Ottawa Institute of Systems Biology, Ottawa, Canada
Rachel Dvorak
Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
Lindsay Meyerdirk
Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States
Michael X Henderson
Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
Maxime WC Rousseaux
Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States; Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Canada; University of Ottawa Brain and Mind Research Institute, Ottawa, Canada; Ottawa Institute of Systems Biology, Ottawa, Canada
Patrik Brundin
Pharma Research and Early Development (pRED), F. Hoffman-La Roche, Little Falls, United States
Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
The presynaptic protein α-synuclein (αSyn) has been suggested to be involved in the pathogenesis of Parkinson’s disease (PD). In PD, the amygdala is prone to develop insoluble αSyn aggregates, and it has been suggested that circuit dysfunction involving the amygdala contributes to the psychiatric symptoms. Yet, how αSyn aggregates affect amygdala function is unknown. In this study, we examined αSyn in glutamatergic axon terminals and the impact of its aggregation on glutamatergic transmission in the basolateral amygdala (BLA). We found that αSyn is primarily present in the vesicular glutamate transporter 1-expressing (vGluT1+) terminals in the mouse BLA, which is consistent with higher levels of αSyn expression in vGluT1+ glutamatergic neurons in the cerebral cortex relative to the vGluT2+ glutamatergic neurons in the thalamus. We found that αSyn aggregation selectively decreased the cortico-BLA, but not the thalamo-BLA, transmission; and that cortico-BLA synapses displayed enhanced short-term depression upon repetitive stimulation. In addition, using confocal microscopy, we found that vGluT1+ axon terminals exhibited decreased levels of soluble αSyn, which suggests that lower levels of soluble αSyn might underlie the enhanced short-term depression of cortico-BLA synapses. In agreement with this idea, we found that cortico-BLA synaptic depression was also enhanced in αSyn knockout mice. In conclusion, both basal and dynamic cortico-BLA transmission were disrupted by abnormal aggregation of αSyn and these changes might be relevant to the perturbed cortical control of the amygdala that has been suggested to play a role in psychiatric symptoms in PD.